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Abstract The effect of cAMP on the transcriptional activity of
the HIV-1 long terminal repeat/enhancer was investigated and
compared to the effect of cAMP on virus replication. In culture
cAMP repressed virus replication in vivo using different cell
types. Transient transfection studies with HIV-1 enhancer-
derived luciferase reporter gene constructs identified the minimal
DNA sequence mediating the negative regulatory effect of
cAMP on HIV-1 transcription. A single nuclear factor UB
element from the HIV-1 enhancer mediates the repressive effect
on transcription. AP-2 is not involved in cAMP repression.
Stable transfection of Jurkat T cells with the co-activators
CREB binding protein (CBP) and p300 completely abolished the
cAMP repressive effect, supporting the hypothesis that elevation
of intracellular cAMP increases phosphorylation of CREB,
which then competes with phosphorylated p65 and Ets-1 for
limiting amounts of CBP/p300 thereby mediating the observed
repressive effect on transcription. These findings suggest an
important role of cAMP on HIV-1 transcription. ß 2001 Fed-
eration of European Biochemical Societies. Published by Elsev-
ier Science B.V. All rights reserved.
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1. Introduction
The human immunode¢ciency viruses HIV-1 and HIV-2 are
the etiological agents of AIDS [1^3]. Viral transcription is
controlled by cellular factors that interact with sequences lo-
cated in the HIV long terminal repeat (LTR) [4^6]. The HIV-1
core enhancer, which extends from position 3109 to 379,
represents the major regulatory domain and contains overlap-
ping nuclear factor UB (NF-UB), Ets and AP-2 binding sites
[7^13].
The transcription factor NF-UB plays a major role in the
regulation of HIV-1 gene expression [9]. The predominant
form of this transcription factor is a heterodimer consisting
of 50-kDa (p50) and 65-kDa (p65 or RelA) subunits [14,15].
Upon stimulation, cytoplasmic NF-UB bound to inhibitory
IUB proteins is released, translocates to the nucleus, binds to
its DNA binding sites and up-regulates gene expression
[16,17]. NF-UB plays a central role in the up-regulation of
HIV LTR reporter constructs or of proviral sequences in
chronically infected cell lines [18^20].
The transcription factor AP-2 is a sequence-speci¢c DNA
binding protein involved in cAMP induction and shows no
similarity to other known transcription factors. AP-2 contains
a proline-rich transcriptional activation domain and a helix-
span-helix structure [21]. Perkins et al. demonstrated a mutu-
ally exclusive binding of AP-2 and NF-UB to the HIV-1 en-
hancer region [10]. The role of AP-2 in HIV gene regulation
remains to be de¢ned.
Another important and ubiquitous regulatory molecule is
cAMP. It coordinates diverse metabolic processes, and in-
duces the expression of numerous genes through protein ki-
nase A (PKA)-mediated phosphorylation of cAMP response
element (CRE) binding factors, including CREB [22]. Many
genes are regulated and their rate of transcription is rapidly
altered by cAMP [23^28]. In transformed T cells, NF-UB ac-
tivation was inhibited by elevated cAMP levels [29,30], while
the nuclear translocation of NF-UB complexes was not af-
fected [31]. As cAMP can inhibit proin£ammatory cytokines,
agents that raise intracellular cAMP levels such as pentoxy-
philline or rolipram have been tested for potentially bene¢cial
e¡ects [32]. However, the e¡ects of cAMP on HIV transcrip-
tion remain controversial [33,34].
We studied the mechanism of cAMP action on the HIV-1
LTR. Virus production assays showed a negative e¡ect of
cAMP on the production of HIV-1, both in primary human
lymphocytes and in T cell lines. We also found a repressive
e¡ect of cAMP on HIV-1 LTR transcription in primary blood
lymphocytes and human T cell lines. In transient transfection
experiments, this inhibitory e¡ect was mediated by NF-UB
binding sites in the HIV-1 enhancer region. The overlapping
AP-2 binding site is not involved in cAMP-mediated repres-
sion of the HIV-1 enhancer. Finally we show that a stable
transfection of Jurkat T cells with expression constructs of
the co-activators CREB binding protein (CBP) or p300 com-
pletely abolished the cAMP repressive e¡ect.
2. Materials and methods
2.1. Reagents
Phorbol 12-myristate 13-acetate (PMA), phytohemagglutinin and
sodium metavanadate were purchased from Sigma-Aldrich. All
enzymes used for cloning as well as the non-radioactive reverse
transcriptase assay were bought from Boehringer Mannheim/Roche.
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8-Bromoadenosine-3P,5P-monophosphate sodium salt (8-Br-cAMP)
was obtained from BioLog Life Science, forskolin from BIOMOL.
2.2. Cell culture conditions
Human Jurkat T cells and human HUT-78 lymphoma cells were
obtained from the American Type Culture Collection. Both cell lines
and peripheral blood lymphocytes (PBLs) were grown in RPMI 1640
with GlutaMax-I (Life Technologies) supplemented with 10% fetal
calf serum (FCS, BioWhittaker). For transfection cells were seeded
at a density of 1U105 cells/ml and grown at 37‡C in an atmosphere of
95% air and 5% CO2.
2.3. HIV-1 virus production assay
For virus production assays three di¡erent cell types were used:
clones of HUT-78 and Jurkat T cells permanently producing HIV-
1LAI and human PBLs prepared from the blood of a HIV-negative
donor which had been freshly infected with HIV-1LAI [37]. 2U105
cells per well were treated with various concentrations of 8-Br-
cAMP (1 mM, 0.5 mM or 0.25 mM). At various time points reverse
transcriptase (RT) activity in cell culture supernates was measured
using a commercial non-radioactive RT assay (Roche) [38]. All experi-
ments were performed in duplicate. Cell growth and viability (by
trypan blue exclusion) were checked by microscopic examination at
least three times per week.
2.4. Isolation of peripheral blood leukocytes
Peripheral blood leukocytes were isolated from 300 ml bu¡y coats
(leukocyte concentrates) which were obtained by a 4 h apharesis from
healthy volunteers. The leukocyte concentrate was diluted 1:1 with
0.9% NaCl solution and layered on top of a Ficoll cushion. After a 30
min centrifugation step the lymphocyte/monocyte layer was collected
from the interphase. After washing three times in phosphate-bu¡ered
saline (PBS), the cells were cultured and used for transient transfec-
tion experiments and viral production assays as described below.
2.5. Plasmids
The construct containing the full-length HIV-1 LTR sequence up-
stream of a luciferase reporter gene and the tat expression construct
(pSV2tat72) were kindly provided by R. Brack-Werner (GSF Munich,
Germany). The pCMV-CBP and the pCMV-p300 expression plasmids
were a kind gift of Dr. C. Glass (University of California, San Diego,
CA, USA) and have been described previously [35]. The plasmid pRc/
CMV (Invitrogen) contains as a dominant selectable marker the neo
gene under control of the SV40 early promoter allowing selection of
stably transfected cells with the neomycin analogue Geneticin (G418).
Additional luciferase plasmids were generated by inserting double-
stranded oligonucleotides with BglII/BamHI compatible ends into
the BglII site of the pGL3 promoter vector (Promega) in sense and
antisense orientation. The HIV-A double-stranded oligonucleotide
was inserted into a SmaI-digested pGL3 promoter vector (Promega).
For the HIV-AB trimer and HIV-AB trimer/AP-2m luciferase con-
structs three copies of the corresponding oligonucleotides were cloned
in a head to tail orientation into the BglII site of the pGL3 promoter
vector (Promega). The following oligonucleotides were used (only the
sequences of the sense strands are shown):
HIV-A: 5P-CCAAGGGACTTTCCGCTG-3P
HIV-AB monomer/BglII/BamHI: 5P-GATCCCAAGGGACTTTC-
CGCTGGGGACTTTCCAGGA-3P
HIV-AB monomer/AP-2m/BglII/BamHI: 5P-GATCCCAAGGGA-
CTTTCCATATGGGACTTTCCAGGA-3P.
2.6. Transient transfections and luciferase assays
For transient transfection experiments, aliquots consisting of
5U106 proliferating Jurkat T cells or PBLs were pelleted (5 min at
850 rpm), resuspended in 10 ml transfection medium [36] containing
10 Wg plasmid DNA of the corresponding luciferase construct and
incubated for 1 h at 37‡C. For co-transfection experiments with tat,
the transfection mix was supplemented with 5 Wg pSV2tat72 plasmid
DNA. All plasmid DNAs used for transfection experiments were pre-
pared by alkaline lysis and puri¢ed by two consecutive CsCl gradients.
To increase transfection e⁄ciency, a dimethylsulfoxide (DMSO)
shock was performed after the DEAE dextran treatment (5 min
room temperature, medium with 10% DMSO). Cells were washed
twice with PBS, cultured in RPMI 1640 with GlutaMax-I (Life Tech-
nologies) and FCS and stimulated with PMA (25 ng/ml) and/or 8-Br-
cAMP (1 mM) for 12 h. Cells were harvested, and washed three times
with PBS before they were lysed for 10 min on ice by addition of 250
Wl lysis bu¡er (1% Triton X-100, 25 mM glycyl-glycine pH 7.8, 15 mM
MgSO4, 4 mM EGTA pH 8.0, 1 mM dithiothreitol (DTT)). Lysates
were cleared by centrifugation (5 min, 13 000 rpm, 4‡C). Luciferase
enzyme activity was measured as relative light units (RLU) in a lu-
minometer (Berthold Lumat LB9501) by injecting 100 Wl luciferase
assay substrate (Promega) to a tube containing 50 Wl cleared lysate
and 300 Wl of reaction bu¡er (25 mM glycyl-glycine pH 7.8, 15 mM
MgSO4, 4 mM EGTA, 15 mM K2PO4 pH 7.8, 1 mM DTT, 2 mM
ATP). A suitable aliquot of the lysate was used to determine the
protein concentration with a commercial Bradford assay. RLUs
were corrected for 10 Wg of protein after subtraction of the luciferase
background value.
2.7. Generation of stably transfected cells
For the generation of CBP or p300 overexpressing cell lines, Jurkat
Fig. 1. In£uence of 8-Br-cAMP on HIV-1 virus production. The
time course of HIV-1 virus production with and without cAMP is
shown. A: Results obtained with a permanently producing HIV-
1LAI Jurkat T cell clone. Similar results were obtained using a HIV-
1LAI HUT-78 cell clone (B) or freshly infected PBLs from a healthy
volunteer (infection at day 33) (C). On day 0 aliquots of 2U105
cells were seeded in the wells of a 96-well plate. After 2, 4 and 7
days HIV-1 RT activity was measured in supernates. The diagrams
show the RT activity of untreated cells (white bars) or cells treated
with 1 mM (black bars), 0.5 mM (hatched bars) or 0.25 mM (gray
bars) 8-Br-cAMP. All experiments were performed in duplicate.
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T cells were stably co-transfected with the plasmids pCMV-CBP or
pCMV-p300 and pRc/CMV. For transfection, 5 Wg of pCMV-CBP or
pCMV-p300 digested with PvuI and 0.5 Wg of pRc/CMV linearized
with XbaI were combined with approximately 5U106 Jurkat T cells in
400 Wl PBS. This mixture was transferred to a GenePulser cuvette with
a 4 mm electrode gap. Electroporation was performed at room tem-
perature using a GenePulser apparatus (Bio-Rad Laboratories) set to
250 V and 960 WF. One day later, stably transfected cells were selected
by adding G418 (Life Technologies) in a concentration of 800 Wg/ml
to the cell culture medium. Previous dose^response experiments had
shown that this concentration was lethal for untransfected Jurkat T
cells. After 15 days of mass culture, limited dilution cloning was
performed to obtain monoclonal cell lines. Three clones of each line
were selected and used for additional experiments.
3. Results
3.1. HIV-1 virus production is repressed by cAMP
To address the question if cAMP has an e¡ect on HIV-1
replication, virus production assays were performed. Fig. 1
shows the results obtained with two human T cell lines and
primary human PBLs. A Jurkat T cell clone stably infected
with HIV-1 was treated with 8-Br-cAMP in three di¡erent
concentrations. Seven days treatment with cAMP reduced vi-
ral replication as determined by RT activity in cell culture
supernates by approximately 40% (Fig. 1A). In HUT-78 cells
stably infected with HIV-1, cAMP was found to repress virus
production up to 60% after 2^4 days of cAMP treatment (Fig.
1B). Comparable results were obtained in primary human
PBLs prepared from an HIV-1-negative donor. Incubation
of freshly HIV-1-infected PBLs with cAMP reduced viral pro-
duction by 50% after 7 days treatment (Fig. 1C). An inhib-
itory e¡ect of cAMP on cell viability or proliferation as an
explanation for these results was ruled out in control experi-
ments (Table 1).
3.2. HIV-1 LTR activity is repressed by cAMP
In order to analyze the e¡ect of cAMP on HIV-1 LTR
transcription (see Fig. 2), transient transfection experiments
were performed. As T cells are a major target of HIV-1,
human PBL preparations and the human Jurkat T cell line
were used for these experiments. Cells were co-transfected
with a luciferase reporter gene construct containing the full-
length LTR sequence of HIV-1 and an expression plasmid
encoding tat to achieve maximal LTR activity. After trans-
fection the cells were treated for 12 h with PMA either alone
or in combination with 8-Br-cAMP prior to determination of
luciferase activity. PMA stimulation led to a more than 180-
fold induction of the HIV-1 LTR in Jurkat T cells and to a
more than 19-fold induction in PBLs. Co-incubation with 8-
Br-cAMP resulted in a marked repressive e¡ect (approx. 60%
repression in Jurkat T cells (Fig. 3A) and more than 80%
repression in PBLs (Fig. 3B). As di¡erent PBL preparations
showed a high degree of variability in transient transfection
experiments, all subsequent experiments were performed in
the Jurkat T cell line.
3.3. The cAMP repressive e¡ect requires only the NF-UB
binding sites from the HIV-1 LTR
After demonstrating a repressive e¡ect of cAMP on HIV-1
Table 1
In£uence of 8-Br-cAMP on cell viability
Percent living cells
Control 100 100 97.8
cAMP 1 day 100 99 100
cAMP 2 days 98.9 100 98.9
cAMP 4 days 97.7 98.7 98.8
cAMP 7 days 98.6 97.2 100
Jurkat cells were grown in 24 well plates in the presence or absence
of 1 mM 8-Br-cAMP for 1, 2, 4 or 7 days as indicated. Cell viabil-
ity was determined by trypan blue exclusion and the percentage of
living cells is given.
Fig. 2. Schematic representation of the HIV-1 LTR- and HIV-1
LTR-derived sequences used in luciferase constructs. The nucleotide
sequence around the two NF-UB binding sites of the HIV-1 en-
hancer is shown. The NF-UB, Ets and AP-2 binding sites are boxed.
The various regions of the HIV-1 LTR included in luciferase con-
structs are depicted in the lower part of the ¢gure together with
their names and the corresponding symbols. Wild-type oligonucleoti-
des are represented by black triangles, whereas oligonucleotides with
wild-type NF-UB sites and a mutated AP-2 site are indicated by
white triangles.
Fig. 3. E¡ect of cAMP on HIV-1 LTR-derived luciferase constructs.
Jurkat T cells (A) and PBLs (B) were transiently co-transfected with
a full-length HIV-1 LTR luciferase and a tat expression construct.
After transfection cells were treated with PMA and/or 8-Br-cAMP.
Luciferase activity was measured in cellular extracts 12 h after
transfection and results are expressed as relative luciferase activities
with the uninduced level set at 1. One relative unit corresponds to
10 181 RLU in A and to 1236 RLU in B. Di¡erent reporter gene
constructs (pGL3-promoter luciferase (C), HIV-A luciferase (D),
HIV-AB monomer luciferase (E), HIV-AB trimer luciferase (F and
G) (see also Fig. 2)), were transiently transfected into Jurkat T cells.
Cells were treated with PMA and/or 8-Br-cAMP (C^F) and/or for-
skolin (G). Results are expressed as relative luciferase activity with
the uninduced level set at 1, except in C. One relative unit corre-
sponds to 29 901 RLU for C, 43 796 RLU for D, 3509 RLU for E,
91 662 RLU for F and 248 573 RLU for G. The experiments shown
were repeated two times with comparable results. Every transfection
experiment was performed in triplicate.
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LTR activity, we sought to determine which sequences within
the LTR were necessary for this repression. The two adjacent
NF-UB binding sites within the HIV-1 enhancer were consid-
ered the most likely candidate sequences and our analysis
focused on that region. Luciferase constructs containing the
complete LTR sequence, one HIV-1 NF-UB binding site
(HIV-A) or both naturally occurring NF-UB binding sites
(HIV-AB monomer) upstream of the herpes simplex virus
(HSV) thymidine kinase (TK) promoter were generated (Fig.
2). To further enhance the e¡ects obtained with the HIV-AB
monomer luciferase construct, three copies of HIV-AB mono-
mer oligonucleotide were inserted in a head to tail fashion
upstream of the HSV TK promoter in pGL3 (HIV-AB trimer)
(see Fig. 2). Transfection of cells with pGL3 promoter alone
revealed only a very low basal luciferase activity (Fig. 3C).
PMA stimulation led to an approximately three-fold induc-
tion of the HIV-A luciferase construct (Fig. 3D) and to an
approximately 40-fold induction of the HIV-AB monomer lu-
ciferase construct (Fig. 3E). The HIV-AB trimer luciferase
construct showed an approximately 60-fold induction after
stimulation with PMA (Fig. 3F). Co-incubation of cells with
PMA and 8-Br-cAMP resulted in 40% repression (HIV-A lu-
ciferase) or 80% repression (HIV-AB monomer luciferase) of
the luciferase activity compared to cells stimulated with PMA
alone (Fig. 3D,E). With the HIV-AB trimer construct 65%
repression was observed after addition of 8-Br-cAMP (Fig.
3F). Treatment of cells with cAMP alone did not lead to
signi¢cant changes in luciferase activity in comparison to un-
treated cells (data not shown). The cAMP repressive e¡ect did
not depend on the method used to increase the intracellular
cAMP levels. When 8-Br-cAMP was replaced by forskolin, an
adenylate cyclase activator, a comparable level of repression
was achieved (compare Fig. 3F and G).
The HIV-1 enhancer luciferase reporter gene constructs did
not contain the TAR element required for tat binding. In
transient transfection experiments comparable results were
obtained with or without co-transfection of the tat expression
plasmid (data not shown). Therefore, tat was omitted in all
transfection experiments using minimal constructs.
3.4. The AP-2 binding site is not involved in cAMP-mediated
repression
The HIV enhancer contains overlapping binding sites for
the transcription factors NF-UB, AP-2 and Ets (see Fig. 2).
Cyclic AMP can induce AP-2 transcription [39,40], and it has
been reported that the binding of NF-UB and AP-2 to the
HIV-1 enhancer is mutually exclusive [10]. To test whether
the AP-2 site is functionally involved in cAMP repression,
transient transfection experiments were performed with a lu-
ciferase construct in which the AP-2 site had been selectively
destroyed by point mutations [10] (see Fig. 2). The construct
contained three copies of the HIV-AB monomer/AP-2m oli-
gonucleotide upstream of the HSV TK promoter in pGL3.
Transient transfection experiments with the HIV-AB trimer
and HIV-AB trimer/AP-2m luciferase constructs showed a
comparable induction of luciferase activity after PMA stimu-
lation. Co-incubation with PMA and 8-Br-cAMP showed the
same degree of repression for the wild-type (80%) and the AP-
2-mutated construct (85%) (Fig. 4).
3.5. CBP and p300 play an important role in the regulation of
the HIV-1 enhancer region by cAMP
The two closely related proteins CBP and p300 represent
important co-activators connecting transcription factors with
the basal transcription machinery [41^44]. It has been re-
ported that CBP and p300 can interact with the p65 subunit
of NF-UB and also with Ets-1 [45^47]. Since PKA-phosphor-
ylated CREB binds to CBP, Parry and Mackman hypothe-
sized that elevated cAMP levels may inhibit NF-UB-mediated
transcription by a competition between CREB and NF-UB for
limiting amounts of CBP/p300 [48]. To test whether CBP or
p300 is the limiting factor in our model system, we attempted
to generate T cell lines overexpressing either human CBP or
human p300. For that purpose Jurkat T cells were stably
Fig. 4. E¡ect of cAMP on a HIV-1 enhancer luciferase construct
with a mutated AP-2 site. A: Transient transfection experiment in
Jurkat T cells with the HIV-AB trimer luciferase construct contain-
ing the wild-type AP-2 site. B: Results of a transfection experiment
with the HIV-AB trimer/AP-2 mutated luciferase construct (see also
Fig. 2). The cells were treated with PMA and/or 8-Br-cAMP imme-
diately after transfection. One relative unit of luciferase activity cor-
responds to 20 563 RLU in A and 7401 RLU in B. Comparable re-
sults were obtained in three separate experiments.
Fig. 5. E¡ect of CBP/p300 on cAMP-mediated repression. A: Nor-
mal Jurkat T cells were transiently transfected with the HIV-AB
monomer luciferase construct and the luciferase activity was mea-
sured in untreated, PMA- and/or 8-Br-cAMP-treated cells. B: Tran-
sient transfection experiment with the HIV-AB monomer luciferase
construct using Jurkat T cells which were stably transfected with a
p300 expression construct. The cells were treated with PMA and/or
8-Br-cAMP. C: Transient transfection experiment using Jurkat T
cells, which were stably transfected with a CBP expression con-
struct. The cells were treated with PMA and/or 8-Br-cAMP and lu-
ciferase activity was measured in cellular extracts 12 h later. Results
are expressed as relative luciferase activities. One relative unit corre-
sponds to 5781 RLU in A, 2831 RLU in B and 21 948 RLU in C.
The ¢gure shows one representative of three independent experi-
ments. For each of the two stable cell lines three independent clones
were tested with comparable results. The transient transfection ex-
periments were performed in triplicate.
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transfected with expression constructs encoding either CBP or
p300 [35]. Three independent clones from both CBP and p300
stable cell lines were selected and further expanded. Subse-
quently, transient transfection experiments were performed
with these clones and wild-type Jurkat T cells using the
HIV-AB monomer luciferase construct. PMA stimulation
was not a¡ected in the stably transfected CBP or p300 cell
lines. In contrast, in both cell lines the suppressive e¡ect of
cAMP was completely abolished (Fig. 5). Taken together
these results suggest that overexpression of CBP or p300 over-
comes the inhibitory e¡ect of cAMP. These results are con-
sistent with the hypothesis that cAMP elevation in PMA-
stimulated cells leads to a competition of phosphorylated
CREB and phosphorylated NF-UB for binding to CBP or
p300 which represent the limiting factors in transcriptional
activation.
4. Discussion
HIV-1 transcription is mainly regulated by the LTR region.
In this study the repressive e¡ect of cAMP on the transcrip-
tional activity of the HIV-1 LTR was investigated and com-
pared to e¡ects of cAMP on virus replication.
The production of HIV-1 was studied both in primary cells
and in immortalized human T cell lines. In Jurkat and HUT-
78 T cell clones stably infected with HIV-1 the virus produc-
tion rates were decreased up to 60% by cAMP (Fig. 1). This
e¡ect was dependent on the incubation time. No clear cAMP
concentration dependence was observed. A cytotoxic e¡ect of
cAMP was ruled out using a cell viability assay (Table 1). To
con¢rm these data in native human T cells, primary PBLs
were infected with HIV-1, and again cAMP reduced HIV-1
replication. Reports on the regulation of the HIV-1 LTR ac-
tivity by cAMP have yielded controversial results [32,34]. In
latently infected cells of the monocyte/macrophage lineage
cAMP interacting with phorbol esters causes an increase in
HIV-1 LTR activity [34]. In contrast, a repressive e¡ect of
cAMP on the HIV-1 LTR was demonstrated in primary T
cells by Navarro and colleagues [33]. Our data obtained in
primary PBLs and human T cell lines con¢rm the results of
Navarro et al. Thus, cAMP e¡ects may be di¡erent in mono-
cytes and T cells. In human PBLs and Jurkat T cells a neg-
ative e¡ect of cAMP on a full-length HIV-1 LTR-controlled
luciferase reporter construct was seen (Fig. 3A,B). The nega-
tive regulatory e¡ect was obtained with 8-Br-cAMP, which is
a membrane-permeable and non-hydrolyzable cAMP ana-
logue. The same e¡ect was also seen with forskolin, which
activates the adenylate cyclase and thereby elevates intracel-
lular cAMP levels (Fig. 3G). These data support an inhibitory
e¡ect of cAMP on the HIV-1 LTR activity in T cells, as also
reported for dB-cAMP, another cAMP analogue, and the
phosphodiesterase inhibitor rolipram [33].
The transcriptional activity of the HIV-1 LTR is critically
dependent on the activation of NF-UB [49]. The HIV-1 en-
hancer contains overlapping binding sites for the transcription
factors NF-UB, AP-2 and Ets (Fig. 2). Various minimal con-
structs containing the HIV-1 NF-UB sequence upstream of an
HSV TK luciferase reporter gene were generated and used in
transient transfection experiments (Fig. 2). Our reporter assay
results show that the NF-UB sites are required not only for the
activation of the HIV-1 LTR, but also for the repression by
cAMP. A single HIV-1 NF-UB sequence is su⁄cient to medi-
ate the stimulatory e¡ect of PMA, as well as the repressive
e¡ect of cAMP (Fig. 3D).
Perkins et al. demonstrated mutually exclusive in vitro
binding of NF-UB and AP-2 to the HIV-1 enhancer region
[10]. They explained this by overlapping recognition sites for
these transcription factors (see Fig. 2). Interestingly, the tran-
scription factor AP-2 can be induced in response to both
cAMP and phorbol esters [39,40]. Therefore the negative reg-
ulatory e¡ect of cAMP on the HIV-1 LTR could potentially
result from competitive binding of AP-2 (activated by cAMP)
instead of NF-UB (as a downstream signalling factor of PMA)
to the HIV-1 enhancer region. According to this hypothesis
HIV-1 LTR activity should decrease with increased binding of
AP-2 instead of NF-UB. To examine this hypothesis an HIV-
AB trimer/AP-2m luciferase construct was generated (accord-
ing to [10]; Fig. 2) and compared with an HIV-AB trimer
construct. Surprisingly, the mutation of the AP-2 binding
site did not abolish the repressive e¡ect of cAMP. Compara-
ble results were obtained using an HIV-AB monomer/AP-2m
luciferase construct (Fig. 4). These data suggest that the core
AP-2 site between the two U elements may be important for
the full transcriptional activity of the HIV-1 enhancer, but is
not required for the repressive mechanism of cAMP, at least
in this model system.
Parry and Mackman proposed that activation of cAMP-
dependent PKA may inhibit NF-UB-mediated transcription
by phosphorylation of proteins, e.g. CREB, which can bind
to CBP only after PKA phosphorylation and which then com-
petes with phosphorylated p65 for limiting amounts of the co-
activator CBP [48]. CBP is a ubiquitously expressed nuclear
phosphoprotein that functions as a co-activator by linking
several transcriptional activators, each activated by di¡erent
agonists, to the basal transcriptional machinery [35,41,42]. In
this context it is of interest that a protein^protein interaction
between Ets-1 and CBP has been reported [47]. To con¢rm
this ‘CBP competition model’, Jurkat T cell lines were stably
transfected with expression constructs for CBP or p300. With
overexpression of CBP or p300 these proteins should no lon-
ger be limiting and hence the cAMP repressive e¡ect should
be lost. This is in fact what the experiments show (Fig. 5).
In summary, a negative e¡ect of cAMP on HIV-1 replica-
tion and on the transcriptional activity of the HIV-1 LTR
could be shown for primary human PBLs and human T cell
lines. The transcription factor AP-2 does not appear to be
involved in repression of HIV-1 enhancer activity by cAMP.
The observed inhibitory e¡ect of cAMP may be explained by
activation of CREB protein which competes with phosphory-
lated NF-UB and Ets-1 proteins for limiting amounts of CBP/
p300.
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